Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q4 FY23 results · Jan–Mar 2023
Caplin Point Laboratories reported revenue from operations of ₹389.28 crore (up 14.8% from Q4 FY22) and net profit of ₹101.24 crore (up 25.3% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 389.28 | 339.24 | +14.8% | 372.07 | +4.6% |
| Other income | 11.40 | 11.51 | −1.0% | 14.15 | −19.4% |
| Total income | 400.68 | 350.75 | +14.2% | 386.22 | +3.7% |
| Profit before tax | 124.05 | 99.92 | +24.1% | 111.73 | +11.0% |
| Net profit for the period | 101.24 | 80.83 | +25.3% | 97.39 | +4.0% |
| Attributable to shareholders of the company | 102.11 | — | — | 97.48 | +4.7% |
| EPS, basic (₹) | 13.45 | 10.43 | +29.0% | 12.86 | +4.6% |
| Net margin (%) | 26.0 | 23.8 | 26.2 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 144.67 | 111.94 | +29.2% | 130.60 | +10.8% |
| Other income | 12.22 | 10.26 | +19.1% | 29.36 | −58.4% |
| Total income | 156.89 | 122.20 | +28.4% | 159.96 | −1.9% |
| Profit before tax | 70.77 | 41.70 | +69.7% | 74.36 | −4.8% |
| Net profit for the period | 54.33 | 29.02 | +87.2% | 59.17 | −8.2% |
| EPS, basic (₹) | 7.15 | 3.83 | +86.7% | 7.80 | −8.3% |
| Net margin (%) | 37.6 | 25.9 | 45.3 |
Consolidated
- Filed with BSE
- 27 May 2023, 18:44 IST
- Board meeting
- 27 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 May 2023, 18:44 IST
- Board meeting
- 27 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE